These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 23663341)

  • 1. [Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression].
    Huang YX; Song L; Zhang X; Lun WW; Pan C; Huang YS
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(8):600-2. PubMed ID: 23663341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of remifemin compared to tibolone for controlling of perimenopausal symptoms].
    Bai WP; Wang SY; Liu JL; Geng L; Hu LN; Zhang ZL; Chen SL; Zheng SR
    Zhonghua Fu Chan Ke Za Zhi; 2009 Aug; 44(8):597-600. PubMed ID: 20003788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of different antidepression therapy in perimenopausal and postmenopausal women with depression].
    Lai AL; Zhao YW; Qi HY; Zhang JS; Zhang LS; Weng YQ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):169-72. PubMed ID: 17537301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
    Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
    Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
    Daléry J; Aubin V
    Encephale; 2001; 27(1):71-81. PubMed ID: 11294041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical observation on treatment of major depressive disorder by paroxetine combined with chaihu xiaoyao mixture].
    Yi ZH; Zhu LP; Long B
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Dec; 30(12):1257-60. PubMed ID: 21302485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine.
    Szegedi A; Kohnen R; Dienel A; Kieser M
    BMJ; 2005 Mar; 330(7490):503. PubMed ID: 15708844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis.
    Ehde DM; Kraft GH; Chwastiak L; Sullivan MD; Gibbons LE; Bombardier CH; Wadhwani R
    Gen Hosp Psychiatry; 2008; 30(1):40-8. PubMed ID: 18164939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
    Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A
    Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression.
    Mihaljevic Peles A; Bozina N; Sagud M; Rojnic Kuzman M; Lovric M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1439-44. PubMed ID: 18550244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
    Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone.
    Chen J; Gao H; Li Q; Cong J; Wu J; Pu D; Jiang G
    Med Sci Monit; 2014 Oct; 20():1950-7. PubMed ID: 25321621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.